



CHECKLIST FOR PRESCRIBERS

Apretude[▼] (cabotegravir) for HIV-1 pre-exposure prophylaxis

This checklist for prescribers is to help evaluate and counsel users of Apretude for HIV-1 pre-exposure prophylaxis (PrEP) at initial and follow-up visits

Instructions: Complete the checklist at each visit and file in individual's medical records

Initial evaluation before prescribing Apretude

- ☐ Individual has been carefully selected and agrees to the required dosing schedule (refer to Prescriber Guide for further information on patient selection)
- ☐ Confirmed individual has negative HIV-1 test prior to initiating Apretude using an antigen/antibody test as well as an HIV-RNA-based test (if a combined testing strategy including both tests is not available, testing should follow local guidelines)
- ☐ Reconfirmed HIV status of individual if clinical symptoms consistent with acute viral infection are present, and recent (<1 month) exposures to HIV-1 are suspected

Counselling before prescribing

- ☐ Counselling on the importance of strict adherence to the dosing schedule to help reduce the risk of HIV-1 acquisition, and the potential development of resistance
- ☐ Counselling on the importance of undergoing regular HIV-1 screening testing to reconfirm HIV-1-negative status
- ☐ Counselling that Apretude does not constitute a complete HIV-1 prevention regimen and should be used with other measures, such as condoms and regular testing for other sexually transmitted infections
- ☐ Counselling that Apretude is not a complete HIV treatment regimen and individuals must commence antiretroviral therapy immediately in the unlikely case they acquire HIV-1
- ☐ Instructed the individual to read the Guide for Users of Apretude and Patient Information Leaflet for more information
- ☐ Advised the individual to book their next injection and record it on the Reminder Card

Follow-up at each scheduled visit

- ☐ Enquired for clinical symptoms of acute viral infection
- ☐ Reconfirmed the individual has an HIV-1-negative status
- ☐ Reassessed the individual, if scheduled dosing of injection or tablets was missed, to ensure resumption of PrEP remains appropriate and that the individual remains at high risk
- ☐ Reiterated importance of adherence to injection schedule
- ☐ Reiterated that Apretude does not constitute a complete HIV-1 prevention regimen and should be used with other measures
- ☐ Reminded the individual to refer to the Guide for Users of Apretude and Patient Information Leaflet for more information
- ☐ Reminded the individual to book their next injection and record it on the Reminder Card

The following only applies if individual wishes to discontinue Apretude:

- ☐ Counselling on alternative forms of non-long-acting PrEP if individual remains at risk of acquiring HIV-1, which should be initiated within 2 months of the last Apretude injection

The following only applies in instances of confirmed or suspected HIV-1 diagnosis:

- ☐ Commenced antiretroviral therapy or
- ☐ Referred the individual for HIV treatment

ViiV Healthcare. Adverse events should be reported.

[Placeholder: please insert local safety reporting information here]

NX-GBL-CBT-CRD-230006. November 2023

